← All trials
NCT04504331
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 13, 2020
- Primary completion
- Oct 31, 2022
- Completion date
- Oct 31, 2023
- First posted
- Aug 7, 2020
- Last posted
- Oct 20, 2020
- Enrollment
- 12
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Stanford UniversityLead sponsor
- National Cancer Institute (NCI)Collaborator
- Stanford UniversityOverall official - principal investigator
- QED Therapeutics, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.